JNJ Johnson & Johnson
- Official Name: JOHNSON & JOHNSON
- Headquarters: One Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, 08933 US
- CEO: Joaquin Duato
- Website: jnj.com
- Key Investor: VANGUARD GROUP INC | 9.72%
- Dedicated Investor: ROBERT WOOD JOHNSON FOUNDATION | 87.12%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 4.341 TOTW | 4.824 - 0.483 | ||
| 2025-07-23 | 2 | Won by 4.924 | 5.366 - 0.442 | ||
| 2025-07-29 | 2R | Won by 3.641 | 2.329 - (1.312) | ||
| 2025-07-30 | 3 | Lost by 0.842 | (2.105) - (1.263) | ||
| 2025-08-06 | 4 | Won by 3.762 | 1.963 - (1.799) | ||
| 2025-08-07 | 1R | Won by 3.007 | 0.614 - (2.393) | ||
| 2025-08-12 | 3R | Lost by 2.389 | (0.453) - 1.936 | ||
| 2025-08-13 | 5 | Won by 0.847 | 2.590 - 1.743 | ||
| 2025-08-20 | 6 | Won by 3.910 | 2.416 - (1.494) | ||
| 2025-08-21 | 2R | Won by 1.794 | 1.364 - (0.430) | ||
| 2025-08-27 | 7 | Won by 2.957 | (1.309) - (4.266) | ||
| 2025-09-03 | 8 | Won by 5.750 | 0.712 - (5.038) | ||
| 2025-09-04 | 3R | Won by 0.099 | 0.456 - 0.357 | ||
| 2025-09-10 | 9 | Lost by 2.623 | (1.256) - 1.367 | ||
| 2025-09-11 | 4R | Lost by 0.212 | 1.572 - 1.784 | ||
| 2025-09-17 | 10 | Won by 5.920 | 0.860 - (5.060) | ||
| 2025-09-17 | 1R | Won by 0.065 | 0.400 - 0.335 | ||
| 2025-09-24 | 11 | Lost by 1.104 | (0.291) - 0.813 | ||
| 2025-10-01 | 12 | Won by 4.348 TOTW | 5.285 - 0.937 | ||
| 2025-10-01 | QF | Won by 2.833 | 0.333 - (2.500) | ||
| 2025-10-08 | 13 | Won by 3.686 | 1.933 - (1.753) | ||
| 2025-10-15 | 14 | Won by 1.620 | 0.750 - (0.870) | ||
| 2025-10-15 | SF | Won by 0.868 | 0.176 - (0.692) | ||
| 2025-10-22 | 15 | Won by 1.173 | 0.863 - (0.310) | ||
| 2025-10-22 | F | Lost by 2.165 | 0.547 - 2.712 |
Latest News
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Busines...
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The bios...
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's bigg...
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submis...
Timothy Schmid Exercises Options, Realizes $4.39M
Highlighted on September 4, it was unveiled in an SEC filing that Schmid, EVP at Johnson & Johnson (NYSE:JNJ), executed a significant transact...
Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?
Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fre...
Protolabs CEO sees big impact from US reshoring despite potential tariffs
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additiona...
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-re...
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 s...
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
AbbVie could take BiTE of Tecvayli market share on Phase III MM win
If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in r...
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State
ISRG Stock: The Best House On The Block Costs The Most
In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational exce...
Discover which dow jones stocks are making waves on Wednesday.
Get insights into the dow jones index performance on Wednesday. Explore the top gainers and losers within the dow jones index in today's session.
The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underly...
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th
How Did Merck Stock Beat The Market With Slowing Sales?
Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.
J&J Jumps as UBS Lifts Its Target to $320
The new objective implies roughly 16% upside and reflects stronger expectations for J&J's pharmaceutical pipeline.
Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says
Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline
Which dow jones stocks are moving on Wednesday?
Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings i...
Dow Adds 300 Points, With Most Stocks Taking Part in the Rally
The Dow was on the rise early in Wednesday's trading session, and the gains were being felt broadly across the blue-chip index. The Dow Jones Ind...
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay inv...
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technolo...
Enovis inks eCential takeover to develop surgical ortho robots
The orthopedics specialist aims to launch a knee robot in late 2028, followed by a shoulder robot in 2029.
UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320
UBS analyst Michael Yee maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $280 to $320.
Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half
Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.
Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?
Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its...
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Three Dividend Kings That Pay a 75-Year-Old $3,900 a Month: KO, JNJ, and PEP
Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yi...
Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2026 Update
GMOâs 13F portfolio jumps to ~$44B. See top holdings, key buys/sells, and rebalancing across tech, healthcare & financialsâread the upda...
Stay informed with the top movers within the dow jones index on Tuesday.
Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.
Stocks rise for first time in four sessions as Treasury yields take breather: Live updates
Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.
These dow jones stocks are moving in today's session
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tue...
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.
Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon t...
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable ...
The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.
Chris Benecchi Named Inventiva’s New Chief Operating Officer
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive ...
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J., August 31, 2026--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesd...
JEPI’s Monthly Payouts Shrunk as the Bull Market Raged. Here’s When That Changes
JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the one event that could reverse both trends is ...
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatmen...
This Popular Healthcare ETF Is Diluting Your Dividend Income
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors ...
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of...
These 3 Dividend Stocks Have Survived Every Recession Since 1970. Retirees Trust Them for a Reason.
Three consumer giants have kept raising their dividends through oil shocks, financial crises, and every other economic storm since 1970, and the cash ...
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Stellantis Appoints Stephanie Hartgrove Chief Communications Officer; Names Clara Ingen-Housz to Lead Public Policy & Regulatory Strategy, International Trade
Stellantis Appoints Stephanie Hartgrove Chief Communications Officer; Names Clara Ingen-Housz to Lead Public Policy & Regulatory Strategy, Interna...
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
One of J&J's investments stands head-and-shoulders above the rest.
Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel
The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in ...